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Background: Research has indicated that the rs12203592 and rs872071 interferon regulatory factor 4 (IRF4) gene
polymorphisms correlate with the risk of cancer, especially skin cancer and haematological malignancies, but the
results remain controversial. To understand better the effects of these two polymorphisms on skin cancer and
haematological malignancies susceptibility, a cumulative meta-analysis was performed.
Methods: We conducted a search using the PubMed and Web of Science databases for relevant case-control
studies published before April 2014. Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs)
were estimated using fixed- or random-effects models where appropriate. Heterogeneity test, publication bias test,
and sensitivity analysis were also performed.
Results: In total, 11 articles comprised of 19 case–control studies were identified; five focused on the rs12203592
polymorphism with 7,992 cases and 8,849 controls, and six were on the rs872071 polymorphism with 3108 cases
and 8300 controls. As for rs12203592, a significant correlation with overall skin cancer and haematological
malignancies risk was found with the homozygote comparison model (OR = 1.566, 95% CI 1.087-2.256) and
recessive model (OR = 1.526, 95% CI 1.107-2.104). For rs872071, a significantly elevated haematological malignancies
risk was observed in all genetic models (homozygote comparison: OR = 1.805, 95% CI 1.402-2.323; heterozygote
comparison: OR = 1.427, 95% CI 1.203-1.692; dominant: OR = 1.556, 95% CI 1.281-1.891; recessive: OR = 1.432, 95% CI
1.293-1.587; additive: OR = 1.349, 95% CI 1.201-1.515). Similarly, increased skin cancer and haematological
malignancies risk was also identified after stratification of the SNP data by cancer type, ethnicity and source of
controls for both polymorphisms.
Conclusions: Our meta-analysis indicated that the rs12203592 and rs872071 IRF4 gene polymorphisms are
associated with individual susceptibility to skin cancer and haematological malignancies. Moreover, the effect of
the rs12203592 polymorphism on skin cancer risk was particularly prominent among Caucasians. Further functional
research should be performed to validate the association.
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Cancer is a multifactorial disease resulting from complex
interactions between environmental and genetic factors.
Cancer is one of the leading causes of death worldwide
[1,2]. Skin cancer is the most common carcinoma, affect-
ing millions worldwide [3]. The two major groups of skin
cancer are non-melanoma and melanoma. The most com-
mon type of non-melanoma skin cancer is basal cell car-
cinoma (BCC) followed by squamous cell carcinoma
(SCC). Melanoma is a malignant tumour of melanocytes.
Melanoma can occur in any part of the body and is
thought to be the most fatal form of skin cancer [4-7].
Haematological malignancies, including leukaemia,
lymphoma and plasma cell dyscrasia, are a group of
disorders that affect blood, bone marrow, lymph nodes
and spleen. These malignancies make up approximately
9.5% of all new cancer diagnoses in the United States [8,9].
Haematological malignancies, such as chronic lymphocytic
leukaemia (CLL), multiple myeloma(MM), Hodgkin lymph-
oma (HL) and non-Hodgkin lymphoma (NHL), are derived
from lymphocyte cells [10,11]. Among these neoplasms,
CLL is the most common form of lymphoid malignancy in
Western countries [12]; malignant lymphoma, generally di-
vided into HL and NHL, is the most common haemato-
logical malignancy in the world. MM is a malignancy of
plasma cells with a complex aetiology [13,14]. However, the
exact mechanism of carcinogenesis remains unclear. In re-
cent years, evidence has revealed that genetic variation can
modulate several important biological processes, thereby al-
tering cancer susceptibility.
Interferon regulatory factors (IRF) are a family of tran-
scription factors characterised by a DNA-binding domain
containing a five-tryptophan residue repeat [15,16]. IRFs
are widely expressed and regulate not only the cellular re-
sponse to interferons but also cell growth, susceptibility to
transformation by oncogenes, induction of apoptosis, and
the development of the T-cell immune response [17]. The
IRF family contains at least ten proteins that modulate the
expression of interferon-inducible genes, considered to
play an important role in the immune response and
tumorigenesis [15,18,19]. As a member of the IRF family
of transcription factors, IRF4 (also known as multiple
myeloma 1 (MUM1) and lymphocyte-specific interferon
regulatory factor (LSIRF)) is expressed in most cell types
of the immune system [20,21]. Recently, IRF4 was re-
ported to be essential to the development and function of
T helper (Th) cells, regulatory T (Treg) cells, B cells and
dendritic cells [22,23]. Research has demonstrated that
IRF4 plays a pivotal role in the development and progres-
sion of cancer, particularly in skin cancer and haematopoi-
etic malignancies [22,24].
Genome-wide association studies (GWAS) are the
ideal strategy to select common, low-penetrance suscep-
tibility loci without prior hypotheses about the role ofthe genes in disease development. Recent GWAS have
reported that variants at several sites within the IRF4
gene may be implicated in the risk of cancer. Most im-
portantly, the intron 4 SNP rs12203592 and 3′ UTR
SNP rs872071 are associated with an increased risk for
melanoma, BCC [25,26], CLL and MM [27,28]. Given
that the IRF4 gene has been recognised as one of the
most common tumour markers, numerous studies have
assessed the possible association between the IRF4 poly-
morphisms and cancer risk. However, the results are in-
conclusive. To derive a more precise estimation of the
relationship between the rs12203592 and rs872071 IRF4
polymorphisms and cancer risk, we performed a meta-
analysis of all available case-control studies.
Methods
Literature search strategy
We searched the PubMed and Web of Science databases
for all relevant articles regarding IRF4 SNPs associated
with cancer risk (search last updated on April 10, 2014).
The following keywords were used: “IRF4” or “interferon
regulatory factor 4”, “polymorphisms or variant or SNP
or mutation” and “cancer or tumor or neoplasm or carcin-
oma”. The search was conducted exclusively on human
subjects. The reference lists of reviews and retrieved arti-
cles were simultaneously hand-searched. We did not con-
sider abstracts or unpublished reports.
Inclusion criteria
All abstracts of citations and retrieved studies were
reviewed. The following criteria were used to identify eli-
gible published studies: (i) the study evaluated the asso-
ciation between the IRF4 polymorphisms (rs12203592
and rs872071) and cancer risk; (ii) the publication was a
case–control or case-cohort study; (iii) the paper pro-
vided sample size, distribution of alleles, genotypes or
other information that can help us estimate an OR with
95% confidence interval (95% CI); (iv) the genotype dis-
tribution of the control population is consistent with
Hardy-Weinberg Equilibrium (HWE). Accordingly, pub-
lications were excluded using the following criteria: (i)
articles that were not about cancer research; (ii) the pub-
lication contained duplicated previous research; (iii) the
study did not include usable genotype data were excluded.
Data extraction
Two investigators independently extracted information
from all eligible publications according to the inclusion
criteria listed above. The results were compared, and
disagreements were resolved by discussion until a con-
sensus was reached. Data extracted from each study in-
cluded the following characteristics: the first author’s
name, the year of publication, the country of partici-
pants, ethnicity, cancer type, source of control group
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type frequency of the rs12203592 and rs872071 poly-
morphism in the cases and controls.
Statistical analysis
All statistical analysis was performed using STATA soft-
ware (version 11.0; STATA Corporation, College Station,
TX). Two sided P-values < 0.05 were considered statisti-
cally significant. Our meta-analysis recalculated HWE in
the controls for each study. The goodness of fit test (chi-
square or Fisher’s exact test) was used to assess deviation
from HWE (significant at the 0.05 level). Studies that de-
viated from HWE were removed.
ORs with 95% CIs were used to estimate the strength
of the association between the IRF4 rs12203592 and
rs872071 polymorphisms and skin cancer and haemato-
poietic malignancies risk. In addition, the Z-test was also
used, and a P value < 0.05 indicated statistical significance
for the association. We examined the association between
the rs12203592 IRF4 polymorphism and skin cancer and
haematopoietic malignancies using the homozygote
comparison (TT versus CC), heterozygote comparison
(CT versus CC), dominant genetic model (TT + CT ver-
sus CC), recessive genetic model (TT versus CT + CC)
and additive genetic model (T versus C). The same
methods were applied to the analysis of the rs872071
IRF4 polymorphism. In addition, a stratified analysis was
also performed based on cancer type, ethnicity and the
source of controls.
The assumption of heterogeneity was ascertained using
a chi-based Q-test. A P-value less than 0.05 for the Q test
indicated significant heterogeneity among the studies. The
pooled OR was estimated using a fixed- or random-effects
model, where appropriate. If the P value was less than
0.05 indicative of heterogeneity across studies, a random-
effects model (DerSimonian and Laird) was utilised for
the meta-analysis [29]. Otherwise, a fixed-effect model
(Mantel-Haenszel) was used [30]. We also quantified the
effect of heterogeneity using the I2 test. I2 values of 25, 50,
and 75% were indicative of low, moderate, and high het-
erogeneity, respectively.
The sensitivity analysis was conducted by removing one
study at a time to evaluate the quality and consistency of
the meta-analysis results. Publication bias was qualitatively
and quantitatively assessed using the Begg’s funnel plots
and Egger’s test, respectively [31]. To ensure the reliability
and the accuracy of the results, two reviewers independ-
ently assessed the data using the statistical software pro-
grammes and obtained the same results.
Results
Literature search and characteristics
A total of 179 potential individual publications were ini-
tially identified after a systematic literature search of thePubMed, Embase and Web of Science databases. The ti-
tles, abstracts and full texts of the retrieved articles were
reviewed based on the inclusion criteria shown in
Figure 1. Finally, we identified 11 eligible articles com-
prised of 19 studies for the current meta-analysis
[24,27,32-40]. In all the eligible articles, studies by Han
et al., Wang et al., Broderick et al., Di Bernardo et al. in-
clude different sets of data, and each set of data was
treated as a separate case–control study in this meta-
analysis (Table 1). Our meta-analysis included 11 of the
rs12203592 polymorphism with 7,992 cases and 8,849
controls and 8 studies of the rs872071 polymorphism with
3108 cases and 8300 controls. All studies were published
in English. The control genotype distributions of all
studies were in accordance with HWE. Detailed study
characteristics included in the current meta-analysis are
presented in Table 1.
Quantitative assessment of the included studies
A summary of the meta-analysis findings on the asso-
ciation between the rs12203592 and rs872071 IRF4
polymorphisms and skin cancer and haematopoietic
malignancies risk is presented in Table 2. With respect to
the rs12203592 polymorphism, a total of 11 studies from
5 articles were included in this meta-analysis. Among the
11 studies, 8 focused on skin cancer and 3 on NHL. Eight
studies used Caucasian populations, and 3 were from USA
with mixed ethnicity. Four studies used population-based
controls, and 7 used hospital-based controls. The overall
analyses suggested a significant association between the
rs12203592 polymorphism and skin cancer and haem-
atopoietic malignancies susceptibility in the homozygote
comparison model (OR = 1.566, 95% CI 1.087–2.256)
and recessive model (OR = 1.526, 95% CI 1.107–2.104,
Figure 2a) using the random-effects model. The results
from the other genetic models were not significant. Spe-
cific data for the rs12203592 polymorphism were strati-
fied by cancer type into the NHL subgroup or the skin
cancer subgroup (melanoma, BBC and SCC). For skin
cancer, a significantly increased risk was observed using
the homozygote comparison model (OR = 1.728, 95% CI
1.145-2.608) and recessive model (OR = 1.808, 95% CI
1.127-2.900). However, no significant association was
observed in the NHL subgroup. In the subgroup
analysis stratified by ethnicity, a significantly elevated
cancer risk was found among Caucasians with the
homozygote comparison model (OR = 1.566, 95% CI
1.087–2.256) and recessive model (OR = 1.526, 95% CI
1.107–2.104) but not among Asian populations with all
genetic models. When stratified by the source of con-
trols, a significantly increased risk was observed in the
hospital-based studies under four genetic models
(homozygote comparison: OR = 2.094, 95% CI 1.314-3.336;
dominant genetic model: OR = 1.314, 95% CI 1.002-1.723;
Figure 1 Flow chart of literature search and study selection.
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additive model OR = 1.35, 95%CI 1.058 -1.725), whereas
no significant association was observed in the population-
based studies for all five genetic models.
With respect to the rs872071 polymorphism, a total of
8 studies from 6 articles were included. Of the 8 eligible
studies, 4 focused exclusively on CLL, 3 on lymphoma
and 1 on MM. Caucasian populations were used in 6
studies, and Asians were assessed in 2. Five of the studies
were population-based controls, and 3 used hospital-
based controls. Overall, a significantly elevated haemato-
logical malignancies risk was associated with the rs872071
polymorphism in all genetic models (homozygote com-
parison: OR = 1.805, 95% CI 1.402-2.323; heterozygote
comparison: OR = 1.427, 95% CI 1.203-1.692; dominant:
OR = 1.556, 95% CI 1.281-1.89; recessive: OR = 1.432, 95%
CI 1.293-1.587, Figure 2b; additive: OR = 1.349, 95% CI
1.201-1.515). After stratification by cancer type (HL and
NHL were merged as lymphoma) and source of con-
trols, a significant association was also observed with all
of the genetic models. When we stratified the studies by
ethnicity, a significant association was also observed in
Caucasians under all genetic models. In Asians, the as-
sociation was significant in all genetic models except for
the recessive genetic model (OR = 1.233, 95% CI 0.924-
1.646). The meta-analysis results for the subgroups are
listed in Table 2.Test of heterogeneity
For the rs12203592 polymorphism, all genetic models
showed significant heterogeneity. After subgroup analysis
by cancer type, the heterogeneity was effectively removed
in the NHL subgroup. In the analysis of ethnicity, the het-
erogeneity significantly disappeared in the mixed sub-
group. When stratified based on the source of controls,
the heterogeneity also disappeared in the population-
based control subgroups. The heterogeneity values are
presented in Table 2.
Significant heterogeneities were observed in the overall
analysis of the association between the rs872071 poly-
morphism and haematological malignancies risk in four
genetic models (homozygote comparison, heterozygote
comparison, dominant genetic model and additive model).
After subgroup analysis by cancer type, the heterogeneity
effectively disappeared in the CLL subgroup and lymph-
oma subgroup. In the analysis of ethnicity, the heterogen-
eity was significantly removed in the Asian population but
remained in the Caucasians. When stratified based on
the source of controls, heterogeneity was not observed
in the hospital-based control subgroups. The heterogen-
eity values are presented in Table 2.
Publication bias and sensitivity analysis
Publication biases of the literature were investigated using
the Begg’s funnel plot and Egger’s test. With respect to the
Table 1 Main characteristics of all studies included in the meta-analysis
rs12203592 Case Control
First author Year Country Ethnicity Cancer type Source of controls CC TC TT CC TC TT HWE
Gathany [24] 2009 USA Mixed NHL PB 730 239 19 605 202 18 0.814
Wang 1 [40] 2009 USA Mixed NHL PB 299 123 13 357 143 15 0.882
Wang 2 [40] 2009 USA Mixed NHL PB 332 157 29 283 160 19 0.541
Kvaskoff [34] 2011 France Caucasians Melanoma HB 654 307 48 871 518 79 0.862
Han 1 [35] 2011 USA Caucasians Melanoma HB 123 54 11 450 163 19 0.369
Han 2 [35] 2011 USA Caucasians Melanoma HB 126 68 20 565 232 29 0.394
Pena-Chilet [32] 2013 Spain Caucasians Melanoma PB 398 121 19 242 101 19 0.055
Han 3 [35] 2011 USA Caucasians SCC HB 156 80 15 450 163 19 0.369
Han 4 [35] 2011 USA Caucasians SCC HB 143 110 20 565 232 29 0.394
Han 5 [35] 2011 USA Caucasians BCC HB 139 54 20 503 191 24 0.269
Han 6 [35] 2011 USA Caucasians BCC HB 174 81 19 565 232 29 0.394
rs872071 Case Control
First author Year Country Ethnicity Cancer type Source of controls AA AG GG AA AG GG HWE
Di Bernardo 1 [27] 2008 UK Caucasians CLL HB 63 248 190 305 720 411 0.754
Di Bernardo 2 [27] 2008 UK Caucasians CLL PB 67 232 201 183 391 202 0.816
Lan [36] 2010 USA Asians CLL HB 21 36 12 602 534 127 0.978
Crowther-Swanepoel [37] 2010 UK Caucasians CLL PB 74 203 117 129 179 89 0.076
Broderick 1 [39] 2010 UK Caucasians HL PB 16 55 36 228 519 278 0.629
Broderick 2 [39] 2010 UK Caucasians HL PB 83 198 118 259 562 269 0.302
Pratt [38] 2010 UK Caucasians MM PB 82 169 101 183 388 200 0.846
Qiao [33] 2013 China Asians NHL HB 341 381 64 777 653 112 0.112
BCC: Basal cell carcinoma; SCC: Squamous cell carcinoma; HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; MM: Multiple myeloma; CLL: Chronic lymphocytic
leukaemia.
PB: population based; HB: hospital based.
HWE: Hardy-Weinberg equilibrium.
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plot suggested no publication bias. The Egger’s test did
not show statistical evidence for publication bias (homo-
zygote comparison model: t = 1.38, P = 0.201). The shapes
of the funnel plots did not reveal any evidence of obvious
asymmetry for the rs872071 polymorphism with all gen-
etic models (Figure not shown). Similarly, the results of
the Egger’s test indicated a lack of publication bias (homo-
zygote comparison model: t =0.61, P = 0.556).
Sensitivity analyses were also performed in the current
meta-analysis to assess the influence of each individual
study on the pooled ORs by sequential removal of indi-
vidual studies. For both the rs12203592 and rs872071
polymorphisms in the IRF4 gene, the results suggested
that no individual study significantly altered the pooled
results, thereby suggesting that the results of this meta-
analysis are robust and reliable (Figure 3a and 3b).
Discussion
IRF4, a member of the IRF family of transcription fac-
tors, is expressed in cells of the immune system and
transduces signals from various receptors to activate orsuppress gene expression [15,41]. The product of the
IRF4 gene is confined to cells of the immune system and
melanocytic lineages [42]. It is considered a key regula-
tor of several steps in lymphoid-, myeloid-, and
dendritic-cell differentiation. It promotes the differenti-
ation of mature B cells into antibody-secreting plasma
cells [43,44]. Additionally, research has revealed that the
IRF4 protein is expressed in a wide spectrum of haem-
atological malignancies and skin cancers [42,45]. IRF4
plays an important role in cancer pathogenesis and acts
as a potential marker for haematological neoplasms and
malignant melanoma [19,45]. Recent GWAS findings
have indicated that variants of the IRF4 gene were asso-
ciated with the susceptibility to some cancer types, in-
cluding CLL, HL, NHL, MM and skin cancer [25-27,35].
Given the possible of the IRF4 gene product in the im-
mune response and carcinogenesis, numerous investiga-
tors have studied the possible association between the
IRF4 polymorphisms and cancer risk, but the results are
somewhat inconclusive. Meta-analysis is a powerful stat-
istical method to combine comparable studies to in-
crease the sample size and statistical power, thereby
Table 2 Main results of pooled ORs and stratification analysis of IRF4 polymorphisms on cancer risk in the meta-analysis
rs12203592 TT vs CC CT vs CC Dominant model Recessive model Additive model
C/T OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa
Overall 1.566 (1.087,2.256)* 0.000 1.070 (0.904,1.266)* 0.000 1.135 (0.941,1.368)* 0.000 1.526 (1.107,2.104)* 0.001 1.168 (0.981,1.392)* 0.000
Source of controls
PB 0.933 (0.672,1.295) 0.403 0.904 (0.793,1.031) 0.320 0.907 (0.799,1.029) 0.265 0.971 (0.701,1.345) 0.420 0.926 (0.830,1.033) 0.215
HB 2.094 (1.314,3.336)* 0.000 1.203 (0.936,1.547)* 0.000 1.314 (1.002,1.723)* 0.000 1.959 (1.310,2.931)* 0.003 1.351 (1.058,1.725)* 0.000
Cancer type
Skin cancer 1.808 (1.127,2.900)* 0.000 1.130 (0.890,1.435)* 0.000 1.217 (0.935,1.584)* 0.000 1.728 (1.145,2.608)* 0.000 1.253 (0.983,1.596)* 0.000
Melanoma 1.315 (0.624,2.770)* 0.000 0.957 (0.724,1.265)* 0.009 1.011 (0.715,1.431)* 0.000 1.321 (0.684,2.552)* 0.001 1.057 (0.747,1.497)* 0.000
BCC 2.511 (1.630,3.867) 0.430 1.085 (0.861,1.368) 0.668 1.245 (1.004,1.543) 0.996 2.451 (1.600,3.755) 0.383 1.352 (1.131,1.617) 0.644
SCC 2.520 (1.598,3.974) 0.703 1.651 (1.330,2.049) 0.208 1.743 (1.418,2.143) 0.207 2.120 (1.354,3.318) 0.901 1.643 (1.385,1.949) 0.303
NHL 1.074 (0.734,1.571) 0.677 0.948 (0.820,1.096) 0.545 0.960 (0.834,1.104) 0.734 1.103 (0.756,1.608) 0.589 0.979 (0.867,1.106) 0.914
Ethnicity
Caucasian 1.808 (1.127,2.900)* 0.000 1.130 (0.890,1.435)* 0.000 1.135 (0.941,1.368)* 0.000 1.728 (1.145,2.608)* 0.000 1.253 (0.983,1.596)* 0.000
Mixed 1.074 (0.734,1.571) 0.677 0.948 (0.820,1.096) 0.545 0.960 (0.834,1.104) 0.734 1.103 (0.756,1.608) 0.589 0.979 (0.867,1.106) 0.914
rs872071 GG vs AA GA vs AA Dominant model Recessive model Additive model
G/A OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa
Overall 1.805 (1.402,2.323)* 0.002 1.427 (1.203,1.692)* 0.034 1.556 (1.281,1.891)* 0.003 1.432 (1.293,1.587) 0.109 1.349 (1.201,1.515)* 0.002
Source of controls
PB 1.767 (1.244,2.511)* 0.003 1.369 (1.041,1.801)* 0.018 1.478 (1.278,1.708)* 0.003 1.443 (1.270,1.639) 0.070 1.329 (1.116,1.582)* 0.002
HB 1.884 (1.212,2.930)* 0.037 1.446 (1.247,1.678) 0.255 1.637 (1.219,2.198) 0.058 1.414 (1.191,1.678) 0.215 1.333 (1.213,1.465) 0.069
Cancer type
CLL 2.424 (1.995,2.945) 0.841 1.752 (1.466,2.093) 0.825 1.982 (1.674,2.346) 0.968 1.646 (1.431,1.892) 0.445 1.543 (1.407,1.692) 0.647
Lymphoma 1.396 (1.123,1.735) 0.614 1.279 (1.103,1.483) 0.472 1.308 (1.135,1.507) 0.579 1.245 (1.039,1.491) 0.754 1.206 (1.095,1.328) 0.764
Ethnicity
Caucasian 1.844 (1.377,2.470)* 0.003 1.418 (1.124,1.787)* 0.019 1.567 (1.214,2.023)* 0.003 1.463 (1.311,1.633) 0.115 1.350 (1.174,1.554)* 0.003
Asian 1.451 (1.072,1.965) 0.075 1.380 (1.164,1.636) 0.205 1.390 (1.180,1.637) 0.109 1.233 (0.924,1.646) 0.167 1.256 (1.110,1.420) 0.071
PB: population based; HB: hospital based; Bold data represent the positive results.
*Random-effects model was used when P value for heterogeneity test < 0.05; otherwise, fix-effects model was used.


















Figure 2 Forest plots of ORs with 95% CIs for IRF4 polymorphisms and cancer susceptibility in the recessive model. (a). rs12203592, TT
versus CT + CC. (b). rs872071, GG versus GA+AA.
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These advantages encouraged us to conduct this meta-
analysis of all published articles investigating the associ-
ation between IRF4 gene polymorphisms and cancer
risk. To our knowledge, this is the first comprehensive
meta-analysis examining the association of two common6p25 variations (rs12203592 and rs872071) and skin
cancer and haematological malignancies susceptibility.
In this meta-analysis, we included 11 eligible articles
comprised of 19 case–control or cohort studies to explore
the association between the rs12203592 and rs872071
IRF4 polymorphisms and skin cancer and haematological
Figure 3 Results of the sensitivity analysis examining the association between the IRF4 and cancer risk polymorphisms and cancer risk
in homozygote comparison model. (a). rs12203592, TT versus CC. (b). rs872071, GG versus AA.
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stratified by cancer type, ethnicity and source of controls.
With respect to the rs12203592 polymorphism, 4901 cases
and 5808 controls were included in the current meta-
analysis. The pooled analyses suggested a significant asso-
ciation between the rs12203592 polymorphism and cancer
susceptibility. In the subgroup analysis based on cancer
type, a significant association was observed between this
polymorphism and cancer risk exclusively in the skin can-
cer subgroup. However, no significant association between
the rs12203592 polymorphism and NHL was found, indi-
cating that the polymorphism may not be an independent
risk factor for the development of NHL. When stratifying
for ethnicity, a significant association was observed in
Caucasian populations but not in other populations, sug-
gesting genetic diversity among different ethnicities. Add-
itionally, after stratification based on the source of
controls, significantly increased risks were found in the
hospital-based studies but not in the population-based
studies. For the rs872071 polymorphism, 3108 cases and
8300 controls were included. Overall, there was evidence
of an association between an increased risk of haemato-
logical malignancies and the rs872071 polymorphism in
all genetic models when all of the eligible studies were
pooled into the meta-analysis. In the subgroup analyses by
cancer type and source of controls, an increased haemato-
logical malignancies risk was also observed in all genetic
models. When stratified by ethnicity, a significantly in-
creased risk was also observed for Asian populations in all
of the genetic models except for the recessive model.
Heterogeneity is a potential problem when explaining
the results of all meta-analyses. In the current study, the
Q-test and I2 statistic were performed to test the signifi-
cance of heterogeneity. For the rs12203592 polymorphism,
significant heterogeneity was found in all comparison
models. When stratified according to cancer type, ethnicity
and source of controls, significant heterogeneity reduced or
disappeared. For the rs872071 polymorphism, significant
heterogeneity was detected in the overall comparisons.
After subgroup analysis by cancer type, the heterogeneity
was effectively decreased or removed. However, significant
heterogeneity still existed Caucasian populations in certain
genetic models when stratified according to ethnicity. This
finding could be attributed to the fact that different
genetic backgrounds and environments exist among
different ethnicities and individuals. When stratified for
the source of controls, significant heterogeneity still
existed in some genetic models for the population-
based studies. In this meta-analysis, the Begg’s funnel
plot and Egger’s test were calculated to evaluate publi-
cation bias. Both the shape of the funnel plots and stat-
istical results did not suggest publication bias. We also
performed sensitivity analysis that indicated the results
were reliable.Several limitations in our meta-analysis should be ac-
knowledged. First, the meta-analysis was based on the
aggregation of published studies; unpublished data, on-
going studies and published articles were excluded.
Studies with negative findings may have biased our re-
sults. Second, the number of cases and controls and
small sample sizes, which could potentially influence the
overall outcome, limited this meta-analysis. Third, most
of the enrolled subjects were Caucasians and Asians; the
populations of other races were under-represented.
Fourth, due to the deficient adjusted data, we computed
raw relative risks (RRs) from frequency distributions re-
ported in the original publications, so our analyses are
not adjusted for the main risk factors of both skin can-
cer and haematological malignancies. In addition, cancer
is a complex disease with a multifactorial aetiology. Lack
of original data for gene-gene and gene-environment in-
teractions limited our further evaluation. Despite these
limitations, the advantages of our meta-analysis should
also be noted. First, studies that satisfactorily met our se-
lection criteria were included in the present meta-
analysis. The substantial number of cases and controls
pooled from the different studies significantly increased
the statistical power of the analysis. Second, the distribu-
tion of genotypes in the controls was in agreement with
Hardy-Weinberg equilibrium (P > 0.05) for all studies.
Third, the results of the Funnel plot and Egger’s test de-
tected no publication bias, indicating that the pooled re-
sult is reliable.
Conclusions
The evidence from the present meta-analysis supports
the notion that both the rs12203592 and rs872071 IRF4
gene polymorphisms are associated with an individual’s
susceptibility to skin cancer and haematological malig-
nancies. The effect of the rs12203592 polymorphism on
cancer is particularly prominent among Caucasians; how-
ever, no significant association with cancer risk was demon-
strated in the NHL subgroup. Based on the limitations of
the present study listed above, further functional studies be-
tween these polymorphisms and cancer risk are warranted.
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